Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Ribo Life Science Co., Ltd.
蘇州瑞博生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6938)

VOLUNTARY ANNOUNCEMENT

INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX AND INCLUSION IN THE STOCK LIST OF STOCK CONNECT SOUTHBOUND TRADING LINK

This announcement is made by Suzhou Ribo Life Science Co., Ltd. (the **"Company"**, together with its subsidiaries, the **"Group"**) on a voluntary basis, which aims to provide the shareholders of the Company (the **"Shareholders"**) and potential investors with information in relation to the latest development of the Company.

The board (the **"Board"**) of directors (the **"Directors"**) of the Company is pleased to announce that, according to the announcement made by Hang Seng Indexes Company Limited, the Company's stock has been included as a constituent stock of the Hang Seng Composite Index, and simultaneously been included in the list of eligible securities of the Southbound Trading Link of the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Scheme (the **"Stock Connect Scheme"**), effective from September 7, 2026.

The inclusion of the Company's stock as a constituent of the Hang Seng Composite Index and as eligible securities under the Stock Connect Scheme represents a significant milestone in the Company's capital market journey, as well as an important step toward the Company's deep integration into both Chinese Mainland and international capital markets and its commitment to supporting the national strategy for high-quality development of the biomedical industry. This inclusion fully reflects strong endorsement from the capital markets for the Company's performance, core value, corporate governance standards and growth potential. Following the implementation of the Stock Connect Scheme, it is expected that the Company's share liquidity will be significantly improved, its investor base broadened, its shareholder structure further optimized, and its visibility and influence in the capital markets enhanced.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, September 7, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.